A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Dorzagliatin, which acts on the glucose sensor glucokinase, is a new class of anti-diabetic medicine. Here the authors report that in a phase I open-label trial co-administration of dorzagliatin and sitagliptin (a different class of anti-diabetic medicine) does not significantly change the pharmacok...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-36946-7 |
| _version_ | 1797864288151404544 |
|---|---|
| author | Li Chen Jiayi Zhang Yu Sun Yu Zhao Xiang Liu Zhiyin Fang Lingge Feng Bin He Quanfei Zou Gregory J. Tracey |
| author_facet | Li Chen Jiayi Zhang Yu Sun Yu Zhao Xiang Liu Zhiyin Fang Lingge Feng Bin He Quanfei Zou Gregory J. Tracey |
| author_sort | Li Chen |
| collection | DOAJ |
| description | Dorzagliatin, which acts on the glucose sensor glucokinase, is a new class of anti-diabetic medicine. Here the authors report that in a phase I open-label trial co-administration of dorzagliatin and sitagliptin (a different class of anti-diabetic medicine) does not significantly change the pharmacokinetics of either medicine in patients with type 2 diabetes and obesity. |
| first_indexed | 2024-04-09T22:49:25Z |
| format | Article |
| id | doaj.art-7c51d01653324f50beb0199d48a473fa |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-09T22:49:25Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-7c51d01653324f50beb0199d48a473fa2023-03-22T11:41:25ZengNature PortfolioNature Communications2041-17232023-03-011411910.1038/s41467-023-36946-7A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesityLi Chen0Jiayi Zhang1Yu Sun2Yu Zhao3Xiang Liu4Zhiyin Fang5Lingge Feng6Bin He7Quanfei Zou8Gregory J. Tracey9Hua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedHua Medicine (Shanghai) LimitedFrontage Clinical Services, Inc.Dorzagliatin, which acts on the glucose sensor glucokinase, is a new class of anti-diabetic medicine. Here the authors report that in a phase I open-label trial co-administration of dorzagliatin and sitagliptin (a different class of anti-diabetic medicine) does not significantly change the pharmacokinetics of either medicine in patients with type 2 diabetes and obesity.https://doi.org/10.1038/s41467-023-36946-7 |
| spellingShingle | Li Chen Jiayi Zhang Yu Sun Yu Zhao Xiang Liu Zhiyin Fang Lingge Feng Bin He Quanfei Zou Gregory J. Tracey A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity Nature Communications |
| title | A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity |
| title_full | A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity |
| title_fullStr | A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity |
| title_full_unstemmed | A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity |
| title_short | A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity |
| title_sort | phase i open label clinical trial to study drug drug interactions of dorzagliatin and sitagliptin in patients with type 2 diabetes and obesity |
| url | https://doi.org/10.1038/s41467-023-36946-7 |
| work_keys_str_mv | AT lichen aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT jiayizhang aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT yusun aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT yuzhao aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT xiangliu aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT zhiyinfang aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT linggefeng aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT binhe aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT quanfeizou aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT gregoryjtracey aphaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT lichen phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT jiayizhang phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT yusun phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT yuzhao phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT xiangliu phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT zhiyinfang phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT linggefeng phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT binhe phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT quanfeizou phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity AT gregoryjtracey phaseiopenlabelclinicaltrialtostudydrugdruginteractionsofdorzagliatinandsitagliptininpatientswithtype2diabetesandobesity |